Rerouting the GPS Directing Immunotherapy in Endometrial Cancer
- PMID: 37698948
- DOI: 10.1158/1078-0432.CCR-23-1953
Rerouting the GPS Directing Immunotherapy in Endometrial Cancer
Abstract
Mismatch repair (MMR) status alone is insufficient to guide the use of PD-(L)1 monotherapy in patients with endometrial cancer. Additional biomarkers, including tumor mutational burden and combined positive score, may help to identify patients with MMR-proficient tumors with a high probability of benefit from PD-(L)1 monotherapy, and those with MMR-deficient tumors who might require combination strategies. See related article by Oaknin et al., p. 4564.
©2023 American Association for Cancer Research.
Comment on
-
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.Clin Cancer Res. 2023 Nov 14;29(22):4564-4574. doi: 10.1158/1078-0432.CCR-22-3915. Clin Cancer Res. 2023. PMID: 37363992 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
